[ NASDAQ: MEIP ] BIO CEO & Investor Conference February 8-9, 2016
|
|
- Gabriella Nichols
- 6 years ago
- Views:
Transcription
1 [ NASDAQ: MEIP ] BIO CEO & Investor Conference February 8-9, 2016
2 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those projected in any of such statements. Additional information concerning factors that may cause actual events or results to differ from those projected is contained in MEI Pharma s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the SEC. 2
3 MEI Pharma (Nasdaq: MEIP) Late-stage oncology drug development company with three wholly owned drug candidates in the clinic Pracinostat: Oral HDAC inhibitor preparing for Phase III study in AML o Median overall survival >14 months in Phase II AML study ME-401 (formerly PWT143): Selective oral PI3K delta inhibitor o Superior clinical PK/PD profile compared to Zydelig ME-344: Novel mitochondrial inhibitor with evidence of clinical activity o Exciting pre-clinical data in combination with VEGF inhibitors Strong intellectual property protection for all three drug candidates Management team w/ proven oncology drug development experience 3
4 Management Team EXECUTIVE MANAGEMENT Daniel Gold, PhD President & Chief Executive Officer Former Chief Scientific Officer & Founder, Favrille Robert Mass, MD Chief Medical Officer Former Head of Medical Affairs, BioOncology, Genentech Thomas Zech Chief Financial Officer Former Chief Financial Officer, Pacira Pharmaceuticals David Urso, JD SVP, Corporate Development & General Counsel Former Principal, Forward Ventures / COO, Tioga Pharmaceuticals Karen Potts, PhD SVP, Regulatory Affairs Former SVP of Regulatory Affairs, Trius Therapeutics BOARD OF DIRECTORS Christine White, MD (Chair) Former Head of Global Medical Affairs, Biogen Idec Charles Baltic, JD Co-Head of Healthcare, Needham & Co. Leah Cann, MBA Two-time Wall Street Journal All-Star Analyst Kevan Clemens, PhD Former Head of Global Oncology, Roche Nick Glover, PhD President & CEO, ProNAi Therapeutics Daniel Gold, PhD President & CEO, MEI Pharma Thomas Reynolds, MD, PhD Former Chief Medical Officer, Seattle Genetics William Rueckert Former Chairman, Novogen Limited 4
5 CANCER METABOLISM PROGRAM SIGNALING PROGRAM EPIGENETICS PROGRAM Clinical Development Pipeline DRUG CANDIDATE INDICATION / COMBINATION PRE-CLINICAL PHASE I PHASE II PHASE III Pracinostat HDAC Inhibitor Acute Myeloid Leukemia Front Line, Elderly Azacitidine (Vidaza ) Myelofibrosis* Front Line & Relapsed/Refractory Ruxolitinib (Jakafi ) REGISTRATION STUDY ME-401 (PWT143) PI3K Delta Inhibitor B-Cell Malignancies Recurrent CLL or follicular NHL Single Agent, Dose Escalation ME-344 Mitochondrial Inhibitor HER2-Negative Breast* Bevacizumab (Avastin ) 5 * Investigator-sponsored studies
6 Pracinostat: Potent & Selective Oral HDAC Inhibitor Tested in 300+ patients in multiple Phase I and II clinical studies Manageable side effects consistent with drugs of this class Potential best-in-class PK profile Enhanced PK profile leads to superior potency On target IC 50 activity for HDAC1 predicted to be >24 hours Evidence of single-agent clinical activity in AML and myelofibrosis Evidence of clinical activity in combination with azacitidine (Aza) Exploratory analyses from randomized Phase II study in MDS suggest benefit for patients able to tolerate Pracinostat for at least 4 cycles Positive results from Phase II study suggest survival benefit in newly diagnosed AML patients 6
7 Pracinostat + Aza in MDS: Summary Pilot study of Pracinostat + Aza in higher risk MDS showed encouraging CR/CRi rate of 89% 1 Randomized Phase II study of Pracinostat + Aza in higher risk MDS failed to improve clinical complete remissions compared to Aza alone Pracinostat resulted in more toxicity when added to Aza, leading to more, and earlier, drug discontinuation in the Pracinostat group Exploratory analyses of patients able to tolerate combination for at least 4 cycles confirm activity of Pracinostat + Aza 7 1 Quintás-Cardama et al. ASH 2012: 3821
8 Pracinostat + Aza in MDS: Overall Survival for Patients on Study for 4 or More Cycles 1 HR = As of data lock on June 30, 2015
9 Pracinostat + Aza in MDS: Duration of Response for Patients on Study for 4 or More Cycles 1 HR = 0.48 HR = As of data lock on June 30, 2015
10 Pracinostat + Aza in AML: Introduction Elderly AML patients, deemed unsuitable for intensive therapy, have limited treatment options Pracinostat has shown single-agent activity in this population 14% (2/14) CR rate in Phase I dose-escalation study 1 Phase II study of Pracinostat + Aza in front line AML designed to assess clinical activity of combination in multi-center environment 10 1 Garcia Manero et al ASH: 3292
11 Pracinostat + Aza in AML: Patient Disposition 1 50 patients have been enrolled at 15 centers FPI: December 24, 2013 LPI: November 24, 2014 n=50 (%) Number of Patients Alive Number of Patients Active Median Observation Time: 14.3 months Number of Patients Discontinued Reasons for discontinuation: Progressive Disease Adverse Event Other* 28 (56) 11 (22) 39 (50) 15 (30) 11 (22) 13 (26) 11 1 As of ASH presentation in December 2015 * Includes patient and/or physician decision
12 Pracinostat + Aza in AML: Overall Survival As of ASH presentation in December 2015
13 Pracinostat + Aza in AML: Association of Survival with CR As of ASH presentation in December 2015
14 MEI-004 vs. AZA-001: Baseline Characteristics MEI-004 AZA Azacitidine + Pracinostat (n=50) Azacitidine (n=241) Age, Years Median Min-max Male gender AML classification (by WHO) Not otherwise specified With myelodysplasia-related changes With therapy-related myeloid neoplasms With recurrent genetic abnormalities* Prior MDS Yes Secondary No * Excluding the provisional entities of AML with NPM1 and AML with CEBPA mutation (molecular data not available) 1 Dombret et al. Blood Jul 16;126(3):291-9
15 MEI-004 vs. AZA-001: Baseline Characteristics MEI-004 AZA Azacitidine + Pracinostat (n=50) Azacitidine (n=241) BM blasts Median Min-max ECOG PS Cytogenetic risk group Intermediate Intermediate, cytogenetically normal Poor Dombret et al. Blood Jul 16;126(3):291-9
16 MEI-004 vs. AZA-001: Overall Population Conventional Care Regimens AZA MEI Azacitidine Azacitidine + Pracinostat Overall Population n=247 n=241 n=50 CR rate 21.9% 19.5% 42.0% 60-day mortality rate 18.2% 16.2% 10.0% 1-year survival rate 34.2% 46.5% 62.0% Event-free survival 4.8 months ( ) 6.7 months ( ) 7.7 months ( ) Duration of response 12.3 months ( ) 10.4 months ( ) 11.2 months ( ) Median overall survival 6.5 months (95%CI: ) 10.4 months (95%CI: ) >14 months (95%CI: 10.7-NR) 16 1 Dombret et al. Blood Jul 16;126(3): Garcia-Manero et al. ASH 2015: 453
17 MEI-004 vs. AZA-001: High-Risk Population Conventional Care Regimens AZA MEI Azacitidine Azacitidine + Pracinostat High-Risk Population n=85 n=85 n=21 1-year survival estimate 14% 30.9% 57.0% Median overall survival 3.2 months 6.4 months 13.3 months 17 1 Döhner et al. ASH 2014: Garcia-Manero et al. ASH 2015: 453
18 Pracinostat + Aza: Management of Toxicities in AML Compared to MDS Patients Phase II studies of Pracinostat: Discontinuations in first two cycles due to tolerability MDS (MEI-003) MDS (MEI-003) AML (MEI-004) 1 Azacitidine (n=51) Azacitidine + Pracinostat (n=51) Azacitidine + Pracinostat (n=50) Cycle Cycle Total 4 (8%) 13 (26%) 4 (8%) 18 1 Garcia-Manero et al. ASH 2015: 453
19 Pracinostat + Aza in AML: Conclusions Combination of Pracinostat + Aza is safe and tolerable in elderly AML High response rate compared to single agent azacitidine Prolonged overall survival compared to single-agent azacitidine Apparent correlation of CR and survival in this low intensity therapy Based on these findings, plan to initiate Phase III registration study in 2 nd half of
20 ME-401: Potential Best-in-Class PI3Kd Inhibitor ME-401 (formerly PWT143) has superior pre-clinical activity compared to other PI3Kd inhibitors, including recently approved Zydelig On-target activity more than 10-fold greater First-in-human, single ascending dose study completed Superior PK/PD profile to Zydelig PK confirms once-daily dosing Expected to have excellent safety margin Phase 1b study in B-cell malignancies anticipated in Q Dose-escalation study in recurrent chronic lymphocytic leukemia (CLL) or follicular non-hodgkin s lymphoma (fnhl) 20
21 ME-401: Superior Pre-Clinical Potency Cell Line Tumor Type IC 50 (um) in Proliferation Assays ME-401 (PWT143) CAL-101 (Zydelig ) PCI (Imbruvica ) Farage DLBCL (GCB) SU-DHL-5 DLBCL (GCB) WSU-NHL DLBCL (GCB) or FL RL DLBCL (GCB) SU-DHL-10 DLBCL (GCB) no data U-2932 DLBCL (ABC) no data 21
22 ME-401: Modeling of PK/PD Data Supports Once-Daily Dosing Biomarker for inhibition of PI3K delta: Inhibition of basophil activation by FceR1 antibody PK/PD data was fit to E max Model EC50 = 0.6 ng/ml (1.0nM) EC90 = 5.2 ng/ml (8.9nM) Daily dosing of > 60 mg expected to afford continuous plasma concentrations above the EC 90 ; i.e. in the plateau of the concentration-inhibition curve 22
23 ME-401: Linear PK & T 1/2 Suitable for Once-Daily Dosing Single ascending dose study now complete: 15 healthy volunteers enrolled in 10, 30, 60, 90 & 150 mg dose levels Mean T 1/2 ~ hr. Independent of dose No reported adverse events 23
24 ME-401: Proposed Phase 1b Clinical Study Objective: Demonstrate therapeutic window in cancer patients RSD = 145 mg, but will start lower to establish MED and will dose escalate to MTD Dose-escalation study in recurrent chronic lymphocytic leukemia (CLL) or follicular non-hodgkin s lymphoma (fnhl) Naïve to phosphatidylinositol-4,5-biphosphate 3 kinase p110d subunit (PI3Kd) and Bruton s tyrosine kinase (BTK) therapies Starting dose = 60 mg q.d. Expected study initiation: Q
25 ME-344: Lead Mitochondrial Inhibitor Mechanism of action directly targets mitochondrial OXPHOS complex I 1, resulting in rapid loss of cellular energy (ATP) Evidence of single agent activity in Phase I dose-escalation study in refractory solid tumors 2 Phase 1b combination study with topotecan in relapsed refractory ovarian & small cell lung cancers demonstrated insufficient activity to warrant further development Exciting pre-clinical data in combination with VEGF inhibitors 3 Expect to initiate an investigator-sponsored combination study with Avastin in HER2-negative breast cancer in Q Lim et al. Am J Cancer Res. 2015;5(2): Bendell et al. Cancer Apr 1;121(7): Manevich et al. AACR 2015: 5409
26 Rationale for ME-344 as Combination Therapy Tumor cells can switch between glycolysis and mitochondrial metabolism for survival + VEGF INHIBITOR + ME-344 Glycolysis Mitochondria SURVIVAL VEGFi DEATH 26
27 ME TKI Inhibit Tumor Growth Synergistically* Tyrosine Kinase Inhibitors (TKI) and ME-344 synergistically modulate glycolysis and oxidative phosphorylation in cancer cells to inhibit tumor growth 1200 Spontaneous Breast Tumor Model 1 Tumor Growth Weeks Vehicle ME-344 BIBF ME TKI #1 BIBF+ME TKI #1 + ME Guy et al Mol Cell Biol 12(3): * Collaboration with Miguel Quintela-Fandino, MD, PhD, Spanish National Cancer Research Centre, Madrid
28 % of Tumor Growth Mouse Xenograft Model: Non-Small Cell Lung Cancer Growth Inhibition Xenograft PULM Vehicle ME344 BIBF BIBF+ME T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 T14 T15 Time (weeks) 28
29 Intellectual Property Pracinostat 4 issued U.S. and 77 issued foreign patents 2 U.S. and 8 foreign applications pending Composition of matter to May, 2028 in U.S. May, 2033 with up to 5 years patent term restoration in U.S. ME-401 (formerly PWT143) 2 issued U.S. patent 1 U.S. and 21 foreign applications pending Composition of matter to Dec in U.S., excluding patent term restoration ME issued U.S. and 18 issued foreign patents 3 U.S. and 7 foreign applications pending Composition of matter to March, 2027 in U.S. March, 2032 with up to 5 years of patent term restoration in U.S. 29
30 Financial Highlights Cash: $53.8 million as of December 31, 2015 Debt: None Shares outstanding: 34.2 million 30
31 2016 Clinical Milestones Median overall survival in Phase II study of Pracinostat + azacitidine in elderly AML Initiation of Phase Ib study of ME-401 in CLL & fnhl (Q2) Initiation of investigator-sponsored study of ME Avastin in HER2-negative breast cancer (Q2) Initiation of Phase III registration study of Pracinostat + azacitidine in elderly AML (2H) Interim data from Phase Ib study of ME-401 in CLL & fnhl (Q4) 31
32 [ NASDAQ: MEIP ] BIO CEO & Investor Conference February 8-9, 2016
[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015
[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More information[ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016
[ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More information[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More information[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016
[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationNeedham Healthcare Conference
Needham Healthcare Conference April 4, 2017 NASDAQ: MEIP Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More information[ NASDAQ: MEIP ] August 2014
[ NASDAQ: MEIP ] August 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationCorporate Presentation
Corporate Presentation October 2017 NASDAQ: MEIP Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially
More informationCorporate Presentation
Corporate Presentation January 2018 ASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are forward-looking
More informationStifel Healthcare Conference
Stifel Healthcare Conference ovember 2017 ASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are forward-looking
More informationNASDAQ: MEIP. Pioneering New Therapies for Cancer September 2017
ASDAQ: MEIP Pioneering ew Therapies for Cancer September 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More informationNewsMakers in the Biotech Industry
ASDAQ: MEIP ewsmakers in the Biotech Industry September 8, 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More information[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011
[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationBuilding a Leading Oncology Franchise
Building a Leading Oncology Franchise January 2019 NASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationDisrupting the Cell Cycle to Treat AML, MDS and other Cancers
CYC 682 Disrupting the Cell Cycle to Treat AML, MDS and other Cancers February 2015 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor provisions of
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationPersonalized Therapeutics The Power of Epigenetics. Company Overview. June 2014
Personalized Therapeutics The Power of Epigenetics Company Overview June 2014 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking statements that involve substantial
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationCorporate Presentation. Curis, Inc All Rights Reserved
Corporate Presentation Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company ) within
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationTarGeting B-Cell Diseases
TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationFor personal use only. A new company with: a new technology platform for cancer drug development a new management team a new Board
A new company with: a new technology platform for cancer drug development a new management team a new Board Disclaimer This presentation is confidential and is not an offer or a recommendation or intended
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationHR 95% Confidence Interval. *no DFS events occurred in AJCC 7 stage I/II TNBC patients treated with NPS plus trastuzumab.
NEWS RELEASE SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2018 San Antonio Breast Cancer
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationAstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma
AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma PUBLISHED17 December 2015Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor,
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationNASDAQ: TGTX. J.P. Morgan Healthcare Conference January 2017
NASDAQ: TGTX J.P. Morgan Healthcare Conference January 2017 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationThe Tumor Microenvironment Company
The Tumor Microenvironment Company June 2018 Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
More informationCorporate Presentation. Curis, Inc All Rights Reserved
Corporate Presentation Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company ) within
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationLAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Boston EQUITY RESEARCH Company Report April 12, 2018 MEI Pharma (MEIP - $1.93) Multiple Shots on Goal in Oncology via Targeting Validated Molecules Leading
More informationDeveloping Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014
Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic Kevin G. McLure, PhD EpiCongress July 2014 Zenith Epigenetics Overview Formed from Resverlogix as an independent
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationA company developing innovative, high-impact drugs for cancer
A company developing innovative, high-impact drugs for cancer Investor Briefing March 2019 ASX: KZA NASDAQ : KZIA Twitter: @KaziaTx Forward-Looking Statements This presentation contains forward-looking
More informationCombination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Guillermo Garcia-Manero, MD 2, Katherine Hearn, RN 2, Rosalie Odchimar-Reissig,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationNovogen Limited. An emerging oncology drug developer with two clinical-stage programs NRT NVGN. April 2017
Novogen Limited An emerging oncology drug developer with two clinical-stage programs NRT April 2017 NVGN Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationSafe Harbor Statement
September 2007 Safe Harbor Statement During the course of this presentation we will make forward-looking statements that involve risks and uncertainties associated with a developing pharmaceutical company.
More informationStemline Therapeutics, Inc.
Stemline Therapeutics, Inc. NASDAQ: STML Corporate Presentation March 2016 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forwardlooking statements. In some
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION APRIL 12, 2018 2018 ATOSSA GENETICS, INC. ALL RIGHTS RESERVED. NASDAQ: ATOS WWW.ATOSSAGENETICS.COM 1 Forward-Looking Statements Some of the information presented herein may contain
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationImbruvica. Imbruvica (ibrutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.41 Subject: Imbruvica Page: 1 of 5 Last Review Date: June 22, 2017 Imbruvica Description Imbruvica
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationSunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights November 10, 2014 7:00 AM ET Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationTransforming Oncology With Precision Cancer Therapeutics. Company Overview January 2017
Transforming Oncology With Precision Cancer Therapeutics Company Overview January 2017 COMPANY OVERVIEW JUNE 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking
More informationParticipating Institutions Insitut Gustave Roussy, Villejuif, France Institut Bergonie, Bourdeaux, France. Sponsor Epizyme, Inc
Phase 1 Study of EPZ-6438 (E7438), an Enhancer of Zeste Homolog-2 (EZH2) Inhibitor: Dose Determination and Preliminary Activity in Non-Hodgkin Lymphoma V. Ribrag, J-C. Soria, B. Thomson, L. Reyderman,
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationMedia Release. Basel, 7 November 2013
Media Release Basel, November 2013 Roche s Gazyva helped people with one of the most common forms of blood cancer live significantly longer without their disease worsening compared to MabThera/Rituxan
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationEndoxifen Clinical Update February 1, 2018
Endoxifen Clinical Update February 1, 2018 107 Spring Street Seattle, WA 98104 USA Forward-looking Statements Some of the information presented herein may contain projections or other forward-looking statements
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationEHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)
EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication) ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS):
More information